Subscribe to our Newsletters !!

    antibody

    Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations

    Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit

    Discovery and development of antibody therapies : Webinar

    Neutralizing antibodies (nAbs) against SARS-CoV-2 represent a promising option for treating COVID-19. Screening a large and diverse antibody phage library has allowed for the rapid discovery of anti-SARS-CoV-2 nAbs. In this expert webinar, find out how high-throughput epitope binning and mapping using using label-free biolayer interferometry (BLI) detection and advanced flow cytometry systems has enabled

    Understanding Thyroglobulin Antibody: What You Need to Know

    TgAb targets thyroglobulin which is a protein that helps in the production of thyroid hormones and is manufactured by the immune system. The thyroid gland manufactures thyroglobulin which is important for metabolism control or regulation, growth or energy expenditure and also as a precursor for thyroxine (T4) along with triiodothyronine’s formation. On the opposite side,